Next Generation Sequencing Data Analysis Market by End-user, Product and Geography - Forecast and Analysis 2023-2027

Next Generation Sequencing Data Analysis Market Size 2023-2027

The next-generation sequencing data analysis market size is estimated to grow by USD 1.48 billion at a CAGR of 21.81% between 2022 and 2027. The market's growth hinges on several factors, including the escalating demand for personalized medicine, the increasing need for early diagnosis of genetic disorders, and the expanding applications in genomics research. Personalized medicine, tailored to individual genetic makeup, is gaining traction for its targeted and more effective treatment approach. The emphasis on early diagnosis of genetic disorders is driving the demand for advanced genetic testing technologies. Moreover, the broadening applications in genomics research, particularly in understanding genetic mechanisms and disease pathways, are fueling market expansion. These trends collectively highlight the growing significance of genetic testing and personalized medicine in healthcare, underscoring the market's growth trajectory.

What will be the Size of the Market During the Forecast Period?

To learn more about this report, Request Free Sample

Market Segmentation 

This report provides a detailed analysis of the market by End-user (Academic research, Clinical research, Pharma and biotech entities, and Hospitals and clinics and others ), Product (Services and NGS commercial software ), and Geography (North America, Europe, Asia, and Rest of World (ROW)).

By End-user

The market share growth by the academic research segment will be significant during the forecast period. The market encompasses DNA sequencing technologies used in genomic science, academic research, and clinical diagnostics. Academic institutions utilize NGS for various applications, such as drug discovery, personalized medicine, and clinical diagnostics.

Get a glance at the market contribution of various segments View a PDF Sample

The academic research segment was valued at USD 183.62 million in 2017.  Key drivers include decreasing sequencing costs, user-friendly software, and the demand for precision medicine. NGS enables the analysis of genomic patterns, epigenetics, and biological processes through sequence analysis tools and algorithms. Applications include oncology, genetic research, and tumor genotyping. NGS protocols aid in identifying somatic driver mutations, germline mutations, and resistance mutations. Cancer-related illnesses, financial irregularities, and healthcare professionals benefit from these tools, machine learning techniques, and cloud-based solutions. Additionally, NGS is applied in agriculture, forensics, and genomic studies. Key technologies include Whole-Genome Sequencing, array-based technologies, and clinical. Hence, these factors are expected to drive the market during the forecast period.

By Product 

Services play an important role in the market, providing specialized expertise and support to users in analyzing and interpreting their NGS data. The market encompasses various services for Exome Sequencing, Targeted Resequencing, De Novo Sequencing, and Methyl Sequencing. Biotechnology and pharmaceutical companies, along with contract research organizations, utilize these services to analyze and interpret their NGS data. The process involves raw data preprocessing, alignment, variant calling, and annotation, employing advanced tools and algorithms. Service providers ensure accuracy and reliability through quality control measures and optimization of parameters. Technologies like Synthesis (SBS) are integral part. Hence, these factors are expected to drive the growth of the services segment in the market during the forecast period.

By Region

For more insights about the market share of various regions View PDF Sample now!

North America is estimated to contribute 48% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period. 

The market is primarily driven by advancements in DNA sequencing technology and its applications in various sectors. In 2022, North America led the market due to increased demand for early diagnosis of diseases, particularly cancer, and the presence of major players like Illumina, Thermo Fisher Scientific, and PerkinElmer. NGS has revolutionized genomic science by decreasing the cost of sequencing, and enabling research in rare diseases, epigenetics, and genomic patterns. Clinical diagnostics, bioinformatics pipelines, and cloud computing solutions are essential components. Sequence analysis tools and algorithms are used to interpret somatic driver mutations, germline mutations, and resistance mutations in biological systems. NGS protocols are crucial in oncology, precise medicine, and genetic research. Cancer-related illnesses, financial irregularities, and healthcare professionals are significant end-users. Technology operators, agriculture, forensics, and genomic studies also utilize these tools, including machine learning techniques and cloud-based solutions. Array-based technologies and clinical data are integral to Whole-Genome Sequencing.

Buy Now Full Report and Discover More

Key Market Players 

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 20 market companies, including:

Agilent Technologies Inc.: The company offers next generation sequencing data analysis such as Hybridization Capture based Target Enrichment for NGS, Alissa Reporter Genomic data analysis software for streamlined NGS secondary analysis.

• Alphabet Inc.
• Bio Rad Laboratories Inc.
• Bionivid Technology Pvt. Ltd.
• Congenica Ltd.
• DNAnexus Inc.
• DNASTAR Inc.
• Eurofins Scientific SE
• F. Hoffmann La Roche Ltd.
• Fabric Genomics Inc.
• Golden Helix Inc.
• HiberCell Inc.
• Illumina Inc.
• Pacific Biosciences of California Inc.
• Partek Inc.
• PierianDx Inc.
• QIAGEN NV
• SciGenom Labs Pvt. Ltd.
• Takara Bio Inc.
• Thermo Fisher Scientific Inc.

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Market Dynamics and Customer Landscape

The market is experiencing significant growth due to the increasing demand for clinical diagnosis and precision medicine in various sectors, including Oncology, Pharma and Biotech, Hospitals and Clinics, and Academic Research. The market is driven by the availability of genomic and proteomic information, which requires advanced Cloud-based software, Algorithms and processing capabilities for tertiary and secondary data analysis. NGS commercial software is essential for DNA sequencing techniques such as Long Read Sequencing and Short Read Sequencing, enabling the identification of genomic patterns and epigenetics in breast cancers and rare diseases. The integration of NGS with cloud computing solutions facilitates the efficient analysis of large datasets, making sequence analysis tools indispensable for genomic research and personalized medicine applications. Oncology precision medicine relies on genomic information for patient treatment, utilizing very long read sequencing for detailed genetic analysis. Tertiary data analysis is typically conducted in-house to derive meaningful insights from the vast amount of genomic data generated. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges. 

Key Market Drivers

The adaptation of personalized medicine is a significant driver in the market. The market is experiencing growth due to the increasing need for personalized medicine. Biotechnology and pharmaceutical companies, as well as contract research organizations, are utilizing these for exome sequencing, targeted resequencing, de novo sequencing, and methyl sequencing. Synthesis technology, such as SBS, facilitates the cost-effective and timely analysis of an individual's genome or specific gene regions. These enables the identification of disease-associated variants, including germline and somatic mutations, providing more precise and effective treatment strategies. Thus, the increasing demand for personalized medicine is one of the major drivers that is expected to boost the growth of the market during the forecast period.

Significant Market Trends

Growing advances in NGS techniques is the major trend driving the growth of the market. This is a crucial segment in the biotechnology industry, driven by advancements in Exome Sequencing, Targeted Resequencing, De Novo Sequencing, and Methyl Sequencing. These techniques have revolutionized the diagnostic and therapeutic landscape in clinical environments, particularly in cancer research. Synthesis (SBS) Technology is the backbone of NGS, enabling Pharmaceutical Companies and Contract Research Organizations to decipher the genetic makeup of diseases and identify potential treatments. The application of NGS in various fields has significantly reduced the cost of sequencing, making it accessible to smaller laboratories. Overall, it is a dynamic and evolving market that continues to shape the future of personalized medicine and research. Hence, these factors are expected to boost the growth of the market during the forecast period.

Major Market Challenges

Challenges in implementing NGS workflow is the major challenge that impedes the growth of the market. Next Generation Sequencing (NGS) is a groundbreaking technology in the fields of biotechnology, pharmaceutical companies, and contract research organizations. It facilitates multiple high-throughput molecular profiling assays, including Exome Sequencing, Targeted Resequencing, De Novo Sequencing, and Methyl Sequencing. Despite its advantages, such as shorter turnaround time and lower costs, NGS encounters challenges. These include the need for expertly chosen analytical software tools for workflows, the development of automation strategies, data storage solutions for the vast amounts of generated data, and ethical and legal considerations. The Synthesis (SBS) Technology underpins NGS, enabling simultaneous sequencing of millions of DNA fragments. Therefore, these factors are expected to impede the growth of the market during the forecast period.

Buy Now Full Report and Discover More

Key Market Customer Landscape

The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

Global Market Customer Landscape

Segment Overview

The market research report provides comprehensive data (region wise segment analysis), with forecasts and estimates in "USD Billion" for the period 2023 to 2027, as well as historical data from 2017 to 2022 for the following segments

• End-user Outlook 
  • Academic research
  • Clinical research
  • Pharma and biotech entities
  • Hospitals and clinics and others

• Product Outlook 
  • Services
  • NGS commercial software

• Region Outlook 
  • North America
    • The U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
    • Rest of Europe
  • Asia
    • China
    • India
  • Rest of the world (ROW)
    • Argentina 
    • Brazil 
    • Australia

Market Analyst Overview

The market is a significant and growing field in the genomic research industry. The use of NGS technology has revolutionized the way genetic information is analyzed, leading to advancements in various sectors such as diagnostics, research, and personalized medicine. NGS data analysis involves the processing and interpretation of massive amounts of genetic data to identify genetic variations and mutations. The market for NGS data analysis is driven by factors such as increasing demand for personalized medicine, growing research in genomics, and technological advancements in NGS technology. The market is expected to grow at a steady pace due to the increasing adoption of NGS technology in various applications.

Furthermore, the market is highly competitive, with key players including companies such as Genomic Health, Illumina, Thermo Fisher Scientific, and Qiagen. These companies are investing heavily in research and development to offer innovative solutions for NGS data analysis. The market for NGS data analysis is expected to grow significantly in the coming years due to the increasing demand for accurate and efficient analysis of genetic data. The market is also expected to be influenced by factors such as regulatory approvals, collaborations, and partnerships between companies. In conclusion, the market is a growing and dynamic field that is expected to continue its growth trajectory in the coming years. The market is driven by various factors such as technological advancements, increasing demand for personalized medicine, and growing research in genomics. The market is highly competitive, with key players investing heavily in research and development to offer innovative solutions for NGS data analysis.

Market Scope
Report Coverage	Details
Page number	153
Base year	2022
Historic period	2017-2021
Forecast period	2023-2027
Growth momentum & CAGR	Accelerate at a CAGR of 21.81%
Market growth 2023-2027	USD 1.48 billion
Market structure	Fragmented
YoY growth 2022-2023(%)	21.57
Regional analysis	North America, Europe, Asia, and Rest of World (ROW)
Performing market contribution	North America at 48%
Key countries	US, Canada, Germany, UK, and China
Competitive landscape	Leading companies, Market Positioning of companies, Competitive Strategies, and Industry Risks
Key companies profiled	Agilent Technologies Inc., Alphabet Inc., Bio Rad Laboratories Inc., Bionivid Technology Pvt. Ltd., Congenica Ltd., DNAnexus Inc., DNASTAR Inc., Eurofins Scientific SE, F. Hoffmann La Roche Ltd., Fabric Genomics Inc., Golden Helix Inc., HiberCell Inc., Illumina Inc., Pacific Biosciences of California Inc., Partek Inc., PierianDx Inc., QIAGEN NV, SciGenom Labs Pvt. Ltd., Takara Bio Inc., and Thermo Fisher Scientific Inc.
Market dynamics	Parent market analysis, Market Forecasting, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for market forecast period.
Customization purview	If our market report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

View Sample PDF at your Fingertips

What are the Key Data Covered in this Market Research Report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the market growth and forecasting of the market between 2023 and 2027
• Precise estimation of the size of the market size and its contribution to the parent market
• Accurate predictions about upcoming market trends and analysis and changes in consumer behavior
• Growth of the market industry across Europe, North America, APAC, South America, and Middle East and Africa
• Thorough market growth analysis of the market’s competitive landscape and detailed information about companies
• Comprehensive market analysis and report on the factors that will challenge the market research and growth of market companies

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch